reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Electrospray or MALDI mass spectrometry | Observed mass compared with theoretical 390.35 Da |
| Purity specification | 95 percent or greater by RP-HPLC | Common convention for research-grade peptide |
| Counter-ion | Acetate or trifluoroacetate | Affects net peptide content of a weighed sample |
| Solution storage | −80 °C as single-use aliquots | Repeated freeze–thaw cycles accelerate loss |
| Main degradation route | Aspartimide formation at Asp-Gly | Produces isoaspartate and related species |
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
In 1669, Christiaan Huygens published a brief account on his laws of collision. Among the quantities he listed as being invariant before and after the collision of bodies were both the sum of their linear momenta as well as the sum of their kinetic energies. However, the difference between elastic and inelastic collision was not understood at the time. This led to the dispute among later researchers as to which of these conserved quantities was the more fundamental. In his Horologium Oscillatorium, Huygens gave a much clearer statement regarding the height of ascent of a moving body, and connected this idea with the impossibility of perpetual motion. His study of the dynamics of pendulum motion was based on a single principle, known as Torricelli's Principle: that the center of gravity of a heavy object, or collection of objects, cannot lift itself. Using this principle, Huygens was able to derive the formula for the center of oscillation by an "energy" method, without dealing with forces or torques.
In February 2013, Essendon announced that they had asked the Australian Sports Anti-Doping Authority (ASADA) to investigate the supplements program that Dank had overseen at their club during the 2012 season. A former player, Kyle Reimers, had claimed that the players were asked to sign waivers and were injected with supplements that were "pushing the boundaries". Another former player, Mark McVeigh countered that the injections were only vitamins and all were completely legal and not on any World Anti-Doping Agency (WADA) banned substance list. Dank left Essendon at the end of the 2012 season, and high-performance manager Dean 'The Weapon' Robinson was suspended from the club after the announcement of the investigation. Stephen Dank controversially admitted to a Fairfax journalist that he had been using thymosin beta 4 on Essendon players. When journalist Nick McKenzie pointed out that that drug was prohibited by WADA under its S2 classification, Dank hesitated and then seemed extremely surprised: "Well, that must have just only come in this year and I will get someone to speak to ASADA about that. That's just mind-blowing." After 24 hours, Dank informed Fairfax media that he was actually really talking about thymomodulin which was a permitted substance. In 2015, the AFL Tribunal found him guilty of trafficking in a number of illicit supplements and banned him from any association with the AFL for life. Since most Australian sporting organisations honour sanctions imposed by other leagues, this had the effect of blackballing Dank from major Australian sport.
Clark University 1909 Fordham University 1912 Harvard University 1936 University of Allahabad 1937 University of Benares 1937 University of Calcutta 1938 University of Oxford 1938 University of Geneva 1945 Swiss Federal Institute of Technology in Zurich 1955 on his 80th birthday In addition, he was:
Sources: en.wikipedia.org
===== MeSH D08.811.399.475 – intramolecular oxidoreductases (EC 5.3) ===== MeSH D08.811.399.475.200 – aldose-ketose isomerases MeSH D08.811.399.475.200.174 – autocrine motility factor MeSH D08.811.399.475.200.350 – glucose-6-phosphate isomerase MeSH D08.811.399.475.200.550 – mannose-6-phosphate isomerase MeSH D08.811.399.475.200.662 – neuroleukin MeSH D08.811.399.475.200.775 – triose-phosphate isomerase MeSH D08.811.399.475.400 – carbon-carbon double bond isomerases MeSH D08.811.399.475.400.700 – steroid isomerases MeSH D08.811.399.475.800 – sulfur-sulfur bond isomerases MeSH D08.811.399.475.800.550 – protein disulfide-isomerase MeSH D08.811.399.475.900 – thromboxane-a synthase
== NMR spectroscopy on large proteins == Traditionally, nuclear magnetic resonance spectroscopy has been limited to relatively small proteins or protein domains. This is in part caused by problems resolving overlapping peaks in larger proteins, but this has been alleviated by the introduction of isotope labelling and multidimensional experiments. Another more serious problem is the fact that in large proteins the magnetization relaxes faster, which means there is less time to detect the signal. This in turn causes the peaks to become broader and weaker, and eventually disappear. Two techniques have been introduced to attenuate the relaxation: transverse relaxation optimized spectroscopy (TROSY) and deuteration of proteins. By using these techniques it has been possible to study proteins in complex with the 900 kDa chaperone GroES-GroEL.
== Background == Gaines originally trained as a chemist and oceanographer, and received a master's degree from Scripps Institution of Oceanography in 1987. She has published peer-reviewed papers in The Journal of Organic Chemistry and the Journal of Chromatography A, as well as essays and short stories in an assortment of journals, literary magazines, and anthologies (Econ Papers, Nature, and The North American Review). She founded the "Fiction Meets Science" research and fellowship program at the University of Bremen.
For voluntary and charitable services to the My Name'5 Doddie Foundation. Helen Ruth Waite. Deputy Director, Family Support, Department for Education. For services to Education. Professor Mark Watson-Gandy. Chair, Biometrics and Forensics Ethics Group. For Public and Voluntary Services. Dr. David Clark Watt. Chair, Fife College. For services to the Economy, to Sport and to Education. Lieutenant Colonel (Rtd) David Ian Whimpenny. Lately Board Trustee, The Royal British Legion. For Voluntary Service. Stephen John Whitton. Head, Border Force Maritime Command, Home Office. For services to Maritime Border Security. Professor Mark Harvey Wilcox. Lately National Clinical Director for Infection Prevention and Control, NHS England and Chair, SAGE Sub-Committee on Hospital Onset Covid Infection. For services to Healthcare, particularly during Covid-19. Howard Wilkinson. Chairman, League Managers Association. For services to Association Football and to Charity. Yvonne Marie Wilks-O'Grady. Philanthropist and Co-Founder, Roots Magazine. For services to Media, to Publishing and to Charity. Professor Bryan Williams. Chair of Medicine, University College London and lately Director of Research, University College London Hospitals NHS Foundation Trust. For services to Medicine. Robert John Williamson, DL. Chief Executive, The Community Foundation Tyne and Wear and Northumberland. For Voluntary and Charitable Services. Stephen John Willmer. Lately Deputy Head France, Security Policy and Operations, Ministry of Defence. For services to Defence and to International Relations. Dr.
Sources: en.wikipedia.org
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.
Yes. Trifluoroacetate and acetate ions remain associated with the peptide after purification, so a weighed quantity of powder contains less peptide than the nominal mass suggests. Certificates that report net peptide content rather than raw weight are more directly comparable between suppliers.
Dilute aqueous solutions are less stable than the dry powder and are usually aliquoted and frozen to avoid repeated freeze–thaw cycles. Lyophilised material is best stored desiccated at −20 °C, protected from light. Working solutions are typically prepared fresh from a frozen aliquot.
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.